{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:37Z","timestamp":1790675977660,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T00:00:00Z","timestamp":1460678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2016,8]]},"abstract":"Abstract<\/jats:title>\n \n Aims<\/jats:title>\n \n The relationship between 1\u2010 and 2\u2010h glucose levels following an oral glucose tolerance test (\n OGTT<\/jats:styled-content>\n ) and long\u2010term mortality was evaluated.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Over a 33\u2010year period, 2138 individuals were followed for all\u2010cause mortality. Fasting and post\u2010\n OGTT<\/jats:styled-content>\n glucose parameters categorized the cohort according to baseline glycaemic status. Four categories were established according to 1\u2010 and 2\u2010h glucose levels (in mmol\/l): group A = 1 h \u2264 8.8 and 2 h < 7.8; group B = 1 h > 8.6 and 2 h < 7.8; group C = 1 h \u2264 8.6 and 2 h = 7.8\u201311.1 (impaired glucose tolerance); group D = 1 h > 8.6 and 2 h = 7.8\u201311.1 (impaired glucose tolerance). Individuals with diabetes at baseline were excluded from the cohort.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n By August 2013, 51% of the study cohort had died. The worst prognosis occurred in group D (73.8% mortality), followed by groups C (67.5%), B and A (57.9% and 41.6%, respectively). When the 2\u2010h glucose value is \u2018normal\u2019 (< 7.8 mmol\/l), the 1\u2010h glucose value > 8.6 mmol\/l is an important predictor of mortality (28% increased risk) compared with group A, controlling for sex, age, smoking,\n BMI<\/jats:styled-content>\n , systolic and diastolic blood pressures. A gradual increased hazard for mortality was seen by study group (hazard ratio = 1.28, 1.60 and 1.76, for groups B, C and D, respectively; group A = reference).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n A 1\u2010h glucose value > 8.6 mmol\/l predicts mortality even when the 2\u2010h level is < 7.8 mmol\/l. However, when the 2\u2010h level is in the impaired glucose tolerance range, the hazard for mortality rises significantly independent of the 1\u2010h value. Individuals at risk for developing diabetes could be identified earlier using the 1\u2010h threshold value of 8.6 mmol\/l, which could avert progression to diabetes and increased mortality.\u202c<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dme.13116","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T02:12:39Z","timestamp":1458526359000},"page":"1060-1066","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["One\u2010hour post\u2010load plasma glucose level during the\n OGTT<\/scp>\n predicts mortality: observations from the Israel Study of Glucose Intolerance, Obesity and Hypertension"],"prefix":"10.1111","volume":"33","author":[{"given":"M.","family":"Bergman","sequence":"first","affiliation":[{"name":"NYU Diabetes Prevention Program NYU School of Medicine New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chetrit","sequence":"additional","affiliation":[{"name":"Unit for Cardiovascular Epidemiology The Gertner Institute for Epidemiology and Health Policy Research Tel Hashomer Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Roth","sequence":"additional","affiliation":[{"name":"The Feinstein Institute for Medical Research Manhasset USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dankner","sequence":"additional","affiliation":[{"name":"Unit for Cardiovascular Epidemiology The Gertner Institute for Epidemiology and Health Policy Research Tel Hashomer Israel"},{"name":"The Feinstein Institute for Medical Research Manhasset USA"},{"name":"Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.05.035"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0225"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1264"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2618"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00201-1"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113761"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00456115"},{"key":"e_1_2_8_9_1","first-page":"375","article-title":"Hyperinsulinemia \u2013 a link between glucose intolerance, obesity, hypertension, dyslipoproteinemia, elevated serum uric acid and internal cation imbalance","volume":"3","author":"Modan M","year":"1987","journal-title":"Diabete Metab"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.28.12.1039"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)90599-0"},{"key":"e_1_2_8_12_1","volume-title":"Lipid Research Clinics Program. Volume 1. Lipid and Lipoprotein Analysis","author":"Manual of Laboratory Operations"},{"key":"e_1_2_8_13_1","first-page":"371","article-title":"Prediabetes and associated disorders","volume":"2015","author":"Buysschaert M","year":"2014","journal-title":"Endocrine"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-9873-6"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2261"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3390-x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.04.006"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0155"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044470"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2102"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010013"}],"updated-by":[{"DOI":"10.1111\/dme.13190","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000}}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13116","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T19:40:58Z","timestamp":1696275658000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/dme.13116"],"URL":"https:\/\/doi.org\/10.1111\/dme.13116","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]},"assertion":[{"value":"2016-03-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}